Induction of TGF-beta in Prostate Cancer Treatment
Author Information
Author(s): G.H. Muir, A. Butta, R.J. Shearer, C. Fisher, D.P. Dearnaley, K.C. Flanders, M.B. Sporn, A.A. Colletta
Primary Institution: The Institute of Cancer Research and Royal Marsden Hospital
Hypothesis
Can TGF-beta synthesis and secretion be induced in human prostate cancer after androgen ablation?
Conclusion
The study shows that extracellular TGF-beta1 can be induced in prostate cancer patients after hormonal treatment.
Supporting Evidence
- Six of seven clinically responding tumors showed up-regulation of extracellular TGF-beta1.
- Three of five relapsed tumors also showed increased TGF-beta1 expression.
- The study suggests that TGF-beta1 may continue to be up-regulated even after cancer relapse.
Takeaway
Doctors found that a substance called TGF-beta can increase in prostate cancer patients after they stop taking hormones, which might help explain why some tumors keep growing.
Methodology
The study involved taking prostate biopsies from patients before and after hormonal treatment and analyzing TGF-beta expression through immunohistochemistry.
Limitations
The study had a small sample size and did not assess androgen receptor content.
Participant Demographics
Five patients with hormonally unresponsive prostate cancer and seven patients responding to hormonal treatment.
Want to read the original?
Access the complete publication on the publisher's website